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Diverse properties of store-operated TRPC channels
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In vascular smooth muscle, store-operated channels (SOCs) contribute to many physiological
functions including vasoconstriction and cell growth and proliferation. In the present work
we compared the properties of SOCs in freshly dispersed myocytes from rabbit coronary
and mesenteric arteries and portal vein. Cyclopiazonic acid (CPA)-induced whole-cell SOC
currents were sixfold greater at negative membrane potentials and displayed markedly different
rectification properties and reversal potentials in coronary compared to mesenteric artery myo-
cytes. Single channel studies showed that endothelin-1, CPA and the cell-permeant Ca2+ chelator
BAPTA-AM activated the same 2.6 pS SOC in coronary artery. In 1.5 mM [Ca2+]o the unitary
conductance of SOCs was significantly greater in coronary than in mesenteric artery. Moreover in
0 mM [Ca2+]o the conductance of SOCs in coronary artery was unaltered whereas the conductance
of SOCs in mesenteric artery was increased fourfold. In coronary artery SOCs were inhibited by
the protein kinase C (PKC) inhibitor chelerythrine and activated by the phorbol ester phorbol
12,13-dibutyrate (PDBu), the diacylglycerol analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) and
a catalytic subunit of PKC. These data infer an important role for PKC in activation of SOCs in
coronary artery similar to mesenteric artery and portal vein. Anti-TRPC1 and -TRPC5 antibodies
inhibited SOCs in coronary and mesenteric arteries and portal vein but anti-TRPC6 blocked
SOCs only in coronary artery and anti-TRPC7 blocked SOCs only in portal vein. Immuno-
precipitation showed associations between TRPC1 and TRPC5 in all preparations but between
TRPC5 and TRPC6 only in coronary artery and between TRPC5 and TRPC7 only in portal
vein. Finally, flufenamic acid increased SOC activity in coronary artery but inhibited SOCs in
mesenteric artery and portal vein myocytes. These data provide strong evidence that vascular
myocytes express diverse SOC isoforms, which are likely to be composed of different TRPC
proteins and have different physiological functions.
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Vascular smooth muscle cells possess non-selective cation
channels, which are activated by several stimuli including
vasoconstrictor agents (Large, 2002). When stimulated
these channels allow the entry of cations, primarily Na+
and Ca2+ ions, to produce membrane depolarization.
These events have been implicated in several physiological
functions such as vasoconstriction and cell growth and
proliferation. (Large, 2002; Beech et al. 2004; Dietrich
et al. 2007; Firth et al. 2007). We have been investigating
the physiological properties of native conductances by
studying ion channel activity with whole-cell and single
channel recording in freshly dispersed vascular myocytes.
Our experiments have revealed that agonists such
as noradrenaline (NA), angiotensin-II (Ang II) and
endothelin-1 (ET-1) evoke two distinct classes of
membrane non-selective cation conductances. First, in
rabbit portal vein and mesenteric, coronary and ear
arteries these vasoconstrictors activate cation channels
with unitary conductances between 13 and 70 pS that
are mediated by diacylglycerol (DAG) in a protein kinase
C (PKC)-independent manner (Helliwell & Large, 1997;
Albert & Large, 2001; Albert et al. 2003; Saleh et al.
2006; Peppiatt-Wildman et al. 2007). These channels
are not stimulated by depletion of intracellular Ca2+
stores with sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA) inhibitors such as cyclopiazonic acid (CPA) and
hence these conductances are termed receptor-operated
channels (ROCs). However, in the same preparations
these vasoconstrictors also induce channel currents with
much smaller unitary conductances (about 2 pS) that
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are mediated by DAG via a PKC-dependent mechanism.
Since these conductances are also evoked by CPA and
other procedures to deplete Ca2+ stores they are called
store-operated channels (SOCs; Albert & Large, 2002a,b;
Saleh et al. 2006; present work). Moreover, the fact that
these channel currents can also be evoked by phorbol esters
and calmodulin (CaM) suggests that they may be gated in
a polymodal manner (Albert et al. 2007).
A notable feature is that ROCs display diverse properties
that are likely to be associated with distinctive physiological
functions. For example, the ROC evoked by noradrenaline
in rabbit ear artery myocytes has high constitutive
activity and therefore contributes to the resting membrane
conductance as well as functioning as a ROC (Albert
et al. 2003). In contrast, in rabbit mesenteric and
coronary artery myocytes, Ang II and ET-1, respectively,
evoke cation currents that demonstrate little spontaneous
activity and are only active in the presence of the agonists
(Saleh et al. 2006; Peppiatt-Wildman et al. 2007). Therefore
these latter conductances are classical ROCs and are
unlikely to contribute to the resting membrane potential.
Also, inositol 1,4,5-trisphosphate (IP3), which is produced
by receptor stimulation, potentiates and accelerates
agonist-evoked ROCs in rabbit portal vein (Albert &
Large, 2003) and coronary artery (Peppiatt-Wildman et al.
2007) but has no effect on the ROC in mesenteric artery
(Saleh et al. 2006). ROCs also demonstrate distinctive
pharmacological profiles in that the agent flufenamic acid
(FFA) potentiates ROCs in portal vein and mesenteric
artery (Inoue et al. 2001; Saleh et al. 2006) but inhibits
the conductance in rabbit ear and coronary arteries
(Albert et al. 2006a; Peppiatt-Wildman et al. 2007). It is
probable that these diverse properties result from different
molecular compositions of the underlying ion channels.
There is increasing evidence that canonical transient
receptor potential (TRPC) proteins are components of
non-selective cation channels in smooth muscle including
TRPC1 as a component of SOCs (Xu & Beech, 2001; Large,
2002; Beech et al. 2004; Albert & Large, 2006; Brueggemann
et al. 2006; Saleh et al. 2006; Albert et al. 2007). Moreover
there is evidence that TRPC channels can exist in both
homo- and heterotetrameric structures (e.g. Strubing et al.
2001; Goel et al. 2002; Hofmann et al. 2002; Mio et al.
2005; Zagranichnaya et al. 2005) and therefore the diverse
characteristics of native channels may result from different
TRPC compositions.
Considerably less is known about the physiological
properties of SOCs in freshly dispersed myocytes but it is
becoming evident that these conductances may also exhibit
diverse characteristics. Recently during experiments on
rabbit coronary artery myocytes we observed that ET-1
evoked a SOC that appeared to have significantly different
characteristics from the SOC previously described in rabbit
mesenteric artery. In the present work we show that
SOCs in these two vascular preparations possess distinct
biophysical properties in terms of unitary conductance
and sensitivity to external Ca2+ ions. In addition the
conductances exhibit distinguishing pharmacology and
differential sensitivity to anti-TRPC antibodies. These
results suggest that these SOC isoforms may consist of
different TRPC subunits in different blood vessels. Some
of these data were published in preliminary form (Albert
et al. 2007).
Methods
Cell isolation
New Zealand White rabbits (2–3 kg) were killed using
i.v. sodium pentobarbitone (120 mg kg−1, in accordance
with the UK Animals (Scientific Procedures) Act 1986).
Right and left anterior descending coronary arteries, first
to fifth order mesenteric arteries and portal vein tissue were
dissected free from fat and connective tissue in physio-
logical salt solution containing (mm): NaCl (126), KCl
(6), glucose (10), Hepes (11), MgCl2 (1.2), CaCl2 (1.5),
pH 7.2 adjusted with 10 m NaOH. An incision was made
along the longitudinal axis of the blood vessels and the
exposed endothelium was gently removed using a cotton
bud. Enzymatic digestion and smooth muscle cell isolation
were subsequently carried out using methods previously
described (Saleh et al. 2006).
Electrophysiology
Whole-cell and single SOC currents were recorded in
voltage-clamp mode using whole-cell recording, cell-
attached, inside out and outside-out patch configurations
(Hamill et al. 1981) with a HEKA EPC 8 patch-clamp
amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany)
at room temperature (20–23◦C). Whole-cell membrane
potential recordings were made in current-clamp mode.
Patch pipettes were manufactured from borosilicate glass
to produce pipettes with resistances of about 5 M for
whole-cell recording and 6–10 M for isolated patch
recording when filled with patch pipette solution. To
reduce ‘line’ noise the recording chamber (vol. ca
150–200 μl) was perfused using two 20 ml syringes,
one filled with external solution and the other used
to drain the chamber, in a ‘push and pull’ technique.
The external solution could be exchanged twice within
30 s. When recording whole-cell and single SOC currents
the holding potential was routinely set at 0 mV and
−80 mV, respectively. To evaluate current–voltage (I–V )
characteristics of whole-cell currents, membrane potential
ramps were applied every 20–30 s between −100 mV and
+100 mV (0.2 V s−1) and in single channel recordings
the membrane potential was manually altered between
−120 mV and +100 mV.
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Whole-cell SOC currents and single SOC currents were
initially recorded onto digital audiotape (DAT) using a
Biologic DRA-200 digital tape-recorder (BioLogic Science
Instruments, Claix, France) at a bandwidth of 5 kHz
(HEKA EPC 8 patch-clamp amplifier) and a sample rate
of 48 kHz. For off-line analysis whole-cell SOC currents
and membrane potentials were filtered at 1 kHz and single
SOC currents at 100 Hz (see below, −3 db, low pass 8-pole
Bessel filter, model LP02, Frequency Devices, Ottawa, IL,
USA) and acquired using a Digidata 1322A and pCLAMP
9.0 (Molecular Devices/MDS Analytical Technologies) at
sampling rates of 5 kHz and 1 kHz, respectively. Data
were captured with a personal computer (Dell Dimension
5150).
Single SOC current amplitudes were calculated from
idealized traces of at least 60 s in duration using the
50% threshold method and analysed using pCLAMP v.9.0
software with events lasting for < 6.664 ms (2 × rise time
for a 100 Hz, −3 db, low pass filter) being excluded from
analysis. Single channel current amplitude histograms
were plotted and fitted with Gaussian curves with the
peak of these curves determining the unitary amplitude
of the single channel currents. Open probability (NPo)
was calculated using the equation:
NPo =
∑
(Onn)
T
where n = number of channels in the patch, On = time
spent at each open level and T = total recording time.
Figure preparation was carried out using Origin 6.0
software (OriginLab Corp., Northampton, MA, USA)
where inward single SOC currents are shown as down-
ward deflections.
Immunoprecipitation and Western blotting
Dissected tissues were either flash frozen and stored at
−80◦C for subsequent use or immediately placed into
10 mg ml−1 RIPA lysis buffer (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) supplemented with protease
inhibitors and then homogenized on ice by sonication
for at least 3 h. The total cell lysate (TCL) was
collected by centrifugation at 1000g for 10 min at 4◦C
and then protein content was quantified using the
Bio-Rad protein dye reagent (Bradford method). TCL
was pre-cleared using A/G agarose beads (Santa Cruz
biotechnology) and immunoprecipitated overnight at
4◦C using the appropriate antibody and A/G agarose
bead conjugate. Alternatively, the immunoprecipitation
protocol was carried out using the Catch and Release
kit (Upstate/Millipore), where spin columns were loaded
with 500 μg of cell lysates, 4 μg of antibody and immuno-
precipitated for 2 h at room temperature.
Protein samples were eluted with Laemmli sample
buffer and incubated at 95◦C for 2 min. One-dimensional
protein gel electrophoresis was performed in 4–12%
Bis-Tris gels in a Novex mini-gel system (Invitrogen) with
20 μg of total protein loaded in each lane. Separated
proteins were electrophoretically transferred onto poly-
vinylidene difluoride membranes in a Bio-Rad trans-blot
SD semi-dry transfer cell or using the iBlot apparatus
(Invitrogen). Blots were incubated for 1–4 h with 5%
(weight/volume) non-fat milk in phosphate-buffered
saline (PBS) containing 0.1% Tween 20 (PBST) to block
non-specific protein binding. Membranes were then
incubated with appropriate primary antibody overnight
at 4◦C. (Where possible alternative antibodies raised
against different epitopes were used for immuno-
precipitation and Western blot analysis.) Following
antibody removal blots were washed for 2 h with
milk/PBST. Blots were subsequently incubated with horse-
radish peroxidase-conjugated goat anti-rabbit (Sigma) or
sheep anti-goat (Santa Cruz) IgG secondary antibody
diluted 1 : 1000–1 : 5000 in milk/PBST, washed 3 times in
PBST, and treated with ECL chemiluminescence reagents
(Pierce Biotechnology, Inc., Rockford, IL, USA) for 1 min
and exposed to photographic films.
All antibodies used for immunoprecipitation and
Western blotting were tested with positive control samples
(rat brain extracts from Santa Cruz Biotechnology for
Alomone TRPC1, C5, C6 and Santa Cruz TRPC5, C6; rat
testis extract from Santa Cruz Biotechnology for Santa
Cruz TRPC1) and negative control samples where the
antigenic peptide was included with the precipitating
antibody or TCL was omitted from the procedure. In all
instances the procedure was repeated with both different
antibodies alternately used for the precipitation or the
Western blotting step and data shown represent n-values
of at least three separate experiments.
Anti-TRPC antibodies
Polyclonal TRPC1, C3, C4, C5 and C6 antibodies
generated in rabbits against intracellular epitopes were
purchased from Alomone Laboratories (Jerusalem, Israel;
n.b. Chemicon, Sigma and Biomol Laboratories retail
anti-TRPC antibodies raised against the same epitopes
as Alomone Laboratories). The selectivity and negligible
cross-reactivity of these anti-TRPC antibodies for their
target proteins have been previously confirmed (Liu
et al. 2005; Zagranichnaya et al. 2005; Sours et al. 2006;
Ju et al. 2007). Alternative polyclonal antibodies for
TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6 generated
in goats against different intracellular epitopes were
purchased from Santa Cruz Biotechnology. The specificity
of these antibodies has also been previously confirmed
(Liu et al. 2005; Zagranichnaya et al. 2005). Polyclonal
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
2466 S. N. Saleh and others J Physiol 586.10
TRPC7 antibody was generated against the sequence Glu-
Lys-Phe-Gly-Lys-Asn-Leu-Asn-Lys-Asp-His-Leu-Arg-Val-
Asn corresponding to positions 843–857 of human and
mouse TRPC7 (Accession nos NP 065122 and NP 036165,
respectively) and previously characterized by Goel et al.
(2002). The synthetic purified peptide was conjugated and
used to immunize rabbits and all procedures were carried
out by Sigma Genosys labs (Cambridge, UK). The anti-
serum was affinity purified using the AminoLink® Plus
immobilization kit and the Melon Gel IgG purification
kit (Pierce) and assessed using Western blotting with an
enzyme-linked immunosorbent assay where pre-immune
serum had no activity.
Solutions and drugs
The bathing solution used to measure whole-cell SOC
currents and single SOC currents in outside-out patches
was K+ free and contained (mm): NaCl (126), CaCl2 (1.5),
Hepes (10), glucose (11), DIDS (0.1), niflumic acid (0.1)
and nicardipine (0.005), pH adjusted to 7.2 with NaOH. In
cell-attached patch experiments the membrane potential
was set to approximately 0 mV by perfusing cells in a KCl
external solution containing (mm): KCl (126), CaCl2 (1.5),
Hepes (10) and glucose (11), pH adjusted to 7.2 with 10 m
KOH. Nicardipine (5 μm) was also included to prevent
smooth muscle cell contraction by blocking Ca2+ entry
through voltage-dependent Ca2+ channels.
The patch pipette solution used to measure whole-cell
SOC currents and SOCs in outside-out patches (intra-
cellular solution) was also K+ free and contained (mm):
CsCl (18), caesium aspartate (108), MgCl2 (1.2), Hepes
(10), glucose (11), BAPTA (10), CaCl2 (4.8, free internal
Ca2+ concentration approximately 100 nm as calculated
using EQCAL software), Na2ATP (1), NaGTP (0.2),
pH 7.2 with Tris. The patch pipette solution used
for both cell-attached and inside-out patch recording
(extracellular solution) was K+ free and contained (mm):
NaCl (126), CaCl2 (1.5), Hepes (10), glucose (11),
TEA (10), 4-AP (5), iberiotoxin (0.0002), DIDS (0.1),
niflumic acid (0.1) and nicardipine (0.005), pH adjusted
to 7.2 with NaOH. In some experiments 1.5 mm CaCl2
was removed and 1 mm BAPTA was added (< 10 nm
free Ca2+). The composition of the bathing solution
used in inside-out experiments (intracellular solution)
was the same as the patch pipette solution used for
whole-cell and outside-out patches except that 1 mm
BAPTA and 0.48 mm CaCl2 were included (free internal
Ca2+ concentration approximately 100 nm). Under these
conditions VDCCs, K+ currents, swell-activated Cl−
currents and Ca2+-activated conductances are abolished
and non-selective cation currents could be recorded in
isolation.
All drugs were purchased from either Calbiochem (UK),
Sigma (UK) or Tocris (UK) and agents were dissolved in
distilled H2O or DMSO (0.1%). DMSO alone had no effect
on SOC activity. The values are the mean of n cells ± s.e.m.
Statistical analysis was carried out using paired (comparing
effects of agents on the same cell) or unpaired (comparing
effects of agents between cells) Students’ t test with the
level of significance set at P < 0.05.
Results
Distinctive properties of CPA-evoked whole-cell
cation conductances in coronary and mesenteric
artery myocytes
In the first series of experiments we compared whole-cell
currents evoked by CPA in coronary and mesenteric
arteries. In these studies internal Ca2+ was clamped at
100 nm with a high concentration of BAPTA (10 mm),
which is the conventional method of recording SOC
activity with whole-cell recording.
It was evident that whole-cell SOC currents in
coronary and mesenteric arteries exhibited markedly
different properties that were highlighted by different
current amplitudes at negative membrane potentials
and current–voltage (I–V ) relationships with distinct
rectification properties and reversal potentials (Er).
Figure 1 shows that bath application of 10 μm CPA
activated whole-cell SOC currents in both preparations
at −80 mV and illustrates that the mean peak amplitude
of −6.4 ± 1.4 pA pF−1 (n = 10) in coronary artery
was sixfold greater than the mean peak amplitude
of −1.1 ± 0.5 pA pF−1 (n = 10) in mesenteric artery.
Moreover Fig. 1B and C illustrates that CPA-evoked
SOC currents in coronary artery had a relatively linear
mean current–voltage (I–V ) relationship with an Er
of +4 ± 1 mV (n = 10) whereas in mesenteric artery
CPA-induced SOC currents displayed a pronounced
outwardly rectifying I–V relationship and an Er of
+22 ± 4 mV (n = 10, P < 0.001). Moreover, current ratios
between coronary and mesenteric artery at −100 and
+100 mV were about 10 and 1, respectively, which further
illustrated differences between the I–V relationships in
these two preparations (Fig. 1C).
These pronounced differences in the biophysical
properties of CPA-evoked whole-cell SOC currents in
coronary and mesenteric arteries strongly indicates that
there are likely to be fundamental differences between the
ion channels underlying the SOCs in these two arterial
preparations.
Single channel properties of SOCs in coronary
and mesenteric arteries
To gain more precise information on the SOCs in the two
preparations we compared the properties of SOCs at the
single channel level.
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Figure 2Aa–c shows that bath application of the endo-
genous coronary vasoconstrictor ET-1 (100 nm, n = 8)
and CPA (10 μm, n = 8) evoked cation channel currents
in cell-attached patches from coronary artery myocytes,
which had slope conductances of 2.6 and 2.7 pS,
respectively, and Er of about 0 mV. Moreover the
cell-permeant Ca2+ chelator BAPTA-AM (50 μm), which
passively depletes internal Ca2+ stores, also evoked channel
currents with similar properties in cell-attached patches
(n = 8, data not shown). These data show that ET-1, CPA
and BAPTA-AM activate the same cation conductance in
coronary artery myocytes which is termed a SOC.
A notable result was that single SOC currents
had different biophysical properties in coronary and
mesenteric arteries. In 1.5 mm [Ca2+]o SOCs in mesenteric
artery had a significantly smaller unitary conductance
of 1.9 ± 0.2 pS (n = 8, Table 1, and previous data, Saleh
et al. 2006) than SOCs in coronary artery, which had
a conductance of 2.6 pS (P < 0.05, Fig. 2Ac, Table 1).
Additionally, in 1.5 mm [Ca2+]o SOCs in mesenteric artery
also had a significantly different mean Er of +15 ± 4 mV
(n = 6) compared to −2 ± 3 mV (n = 7, P < 0.05) in
coronary artery (Table 1).
Figure 1. CPA-evoked whole-cell cation conductances in coronary and mesenteric artery myocytes
Aa and b, original traces showing that 10 μM CPA activated whole-cell SOC currents in coronary and mesenteric
arteries. Vertical deflections represent current responses to voltage ramps from −100 mV to +100 mV. Ba and b,
individual I–V relationships before (dashed line) and during (continuous line) CPA-induced whole-cell SOC currents
in coronary and mesenteric arteries. C, mean I–V relationships of whole-cell SOC currents (n = 10 of each).
Previous work has shown that a distinctive feature
of SOCs in mesenteric artery and in portal vein is
that removing external Ca2+ ions increases unitary
conductance (Albert & Large, 2002a; Saleh et al. 2006)
and therefore we compared the effect of removing [Ca2+]o
on the unitary properties of SOCs in coronary and
mesenteric arteries. Figure 2Ba–c shows that in 0 [Ca2+]o
the unitary conductance of SOCs in coronary artery
was 2.7 ± 0.1 pS (n = 7) and similar to the value in
1.5 mm [Ca2+]o. In contrast in mesenteric artery in 0
[Ca2+]o the conductance of SOCs was increased fourfold
to 7.5 ± 1.4 pS (n = 6, P < 0.05, Table 1). Moreover the
mean Er of SOCs in mesenteric artery was significantly
shifted from +15 ± 4 mV (n = 6) in 1.5 mm [Ca2+]o to
−4 ± 1.3 mV in 0 mm (n = 6, P < 0.05, Fig. 2Bc, Table
1), which corresponds to a permeability ratio of Ca2+
to Na+ ions (PCa/PNa) of about 66 (using equation 3
of Jatzke et al. 2001). In contrast the mean Er of
SOCs in coronary artery was similar in 1.5 mm and
0 mm [Ca2+]o suggesting PCa/PNa of about 1 (Table 1).
These different properties of single channels indicate that
there are two SOC isoforms in coronary and mesenteric
arteries.
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Table 1. Comparison of properties of PKC-activated SOCs in vascular smooth muscle
Coronary artery Mesenteric artery Portal vein
Amplitude of CPA-induced −80 mV 6.5 pA pF−1∗ 1.1 pA pF−1 1.0 pA pF−1a
whole-cell SOC currents at −50 mV
I–V relationships Linear Outwardly rectifying Outwardly rectifying
Whole-cell Er in 1.5 [Ca2+]o +4 mV∗ +22 mV +25 mVa
Unitary conductances
1.5 mM [Ca2+]o 2.6 pS∗ 1.9 pS 2.1 pSa
0 mM [Ca2+]o 2.7 pS∗ 7.5 pS 7.4 pSa
Er in 1.5 mM [Ca2+]o −2 mV∗ +15 mV +23 mVa
Er in 0 mM [Ca2+]o −2 mV −4 mV −4 mVa
Response to IP3 — — ↑b
Response to FFA ↑ ↓ ↓
Sensitivity to anti-TRPC antibodies TRPC1, TRPC5, TRPC6 TRPC1, TRPC5 TRPC1, TRPC5, TRPC7
∗P < 0.05 (coronary versus mesenteric artery and portal vein). aAlbert et al. 2002a; bLiu et al. (2005a).
At −80 mV SOC activity induced by 10 μm CPA in
coronary artery had a mean open probability (NPo) of
1.03 ± 0.27 (n = 8), which was approximately threefold
greater than the mean NPo of 0.38 ± 0.17 (n = 8, P < 0.05)
of SOCs evoked by the same stimulus in mesenteric artery.
This increase in SOC activity in coronary artery does
Figure 2. Activation of single channel currents by ET-1 and CPA in cell-attached patches from coronary
artery
Aa and b, bath application of 100 nM ET-1, and 10 μM CPA activated channel currents at −80 mV. Ac, mean I–V
relationships of ET-1- and CPA-evoked channel currents in coronary artery showing similar conductances of 2.6 pS
and 2.7 pS and Er of about 0 mV. Ba and Bb, comparison of CPA- induced single channel currents in coronary
and mesenteric arteries recorded with 0 mM [Ca2+]o illustrating that SOCs in mesenteric artery have larger unitary
amplitudes at −80 mV. Bc, mean I–V relationships of CPA-evoked SOCs recorded in 0 mM [Ca2+]o showing SOCs
had conductances of 2.7 pS and 7.3 pS in, respectively, coronary and mesenteric arteries and Er of about 0 mV in
both preparations.
not appear to be a difference in the number of channels
per patch since in both preparations there were at least
four to five channels per patch. Moreover kinetic analysis
indicated that SOCs had two open times of about 5 ms and
30 ms in both preparations, which are similar to values in
portal vein (data not shown, Albert & Large, 2002a).
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
J Physiol 586.10 PKC-activated TRPC channels 2469
Therefore the greater probability of channel opening
together with a larger unitary conductance may explain
the much larger inward whole-cell SOC currents
observed at negative potentials in coronary compared
to mesenteric artery. However a thorough comparison
between depletion of internal Ca2+ stores and channel
activation, expression levels and activity of PKC and
expression levels of TRPC proteins is needed between these
two preparations to confirm these ideas.
SOCs in coronary artery are activated by PKC
We have previously shown that PKC is important in
activating SOCs in both mesenteric artery and portal vein
(Albert & Large, 2002b; Saleh et al. 2006). However, our
present work indicates that SOCs in coronary artery have
different biophysical properties from SOCs in mesenteric
artery and therefore we investigated whether this kinase
is also involved in activating SOCs in coronary artery,
especially since Ca2+-independent phospholipase A2 has
been implicated in SOC activation in rat coronary artery
(Smani et al. 2007) and calmodulin also has been proposed
to be involved in action of SOCs in portal vein (Albert et al.
2006b).
Bath application of 3 μm chelerythrine, a PKC inhibitor,
significantly reduced BAPTA-AM-, CPA- and ET-1-evoked
SOC activity in cell-attached patches held at −80 mV
Figure 3. SOCs in coronary artery are activated by PKC
A, BAPTA-AM (50 μM) evoked channel activity in a cell-attached patch held at −80 mV, which was reversibly
inhibited by chelerythrine (3 μM). B and C, show that PDBu (1 μM) and a PKC catalytic subunit (0.05 U ml−1)
activated single channel currents in cell-attached and inside-out patches, respectively. D, mean I–V relationships
of channel currents induced by a PKC catalytic subunit in coronary and mesenteric arteries.
by, respectively, 91 ± 19% (n = 4, P < 0.05, Fig. 3A),
92 ± 10% (n = 4, P < 0.05), and 80 ± 13% (n = 5,
P < 0.05). In addition in both 1.5 and 0 mm [Ca2+]o
bath application of 1 μm phorbol 12,13-dibutyrate
(PDBu), a PKC activator, induced channel currents
in cell-attached patches with unitary conductances of
about 2.6 pS and Er of about 0 mV (n = 6, Fig. 3B),
which are similar to the properties of CPA-induced
SOCs. Moreover PDBu-induced SOC activity (n = 5)
and SOC activity evoked by the cell-permeant DAG
analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG, 10 μm,
n = 4), an activator of endogenous PKC, were inhibited
by chelerythrine by over 90% in cell-attached patches
(data not shown). Figure 3C and D also shows that bath
application of a PKC catalytic subunit (0.05 U ml−1) to the
cytosolic surface of inside-out patches from both coronary
and mesenteric arteries activated channel currents with
similar properties to SOCs induced by CPA.
We have previously shown that IP3 potentiated the
activity of SOCs in portal vein (Liu et al. 2005b) but
had no effect on SOCs in mesenteric artery (Saleh et al.
2006). Therefore we also investigated the effect of IP3 on
SOC activity in coronary artery and showed that bath
application of 10 μm IP3 had no effect on CPA- (n = 6)
or PDBu-evoked SOCs in inside-out patches (data not
shown).
These results show that although SOCs in coronary
artery have different biophysical properties from SOCs in
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mesenteric artery there appears to be a common activation
mechanism involving PKC stimulation.
Effect of anti-TRPC antibodies on SOC activity in
coronary and mesenteric arteries and portal vein
There is evidence that TRPC proteins are components of
SOCs in vascular smooth muscle (Large, 2002; Beech et al.
2004; Albert & Large, 2006; Albert et al. 2007) and therefore
we investigated whether the diverse properties of native
SOCs in coronary and mesenteric arteries were associated
with different sensitivity to anti-TRPC antibodies. This
approach has already demonstrated that ROCs in vascular
smooth muscle have marked differences in sensitivity
to these antibodies indicating diverse TRPC properties
(Albert et al. 2006b; Saleh et al. 2006; Peppiatt-Wildman
et al. 2007). We also investigated the effect of anti-TRPC
antibodies on SOC activity in portal vein since IP3
potentiates SOCs in this preparation (Liu et al. 2005b)
but not in coronary and mesenteric artery (Saleh et al.
2006; present work) suggesting that the channel in portal
Figure 4. Differential sensitivity of SOCs in coronary and mesenteric arteries and portal vein to anti-TRPC
antibodies
Aa, in coronary artery bath application of anti-TRPC1, -TRPC5 and -TRPC6 antibodies at 1: 200 dilution significantly
inhibited SOC activity in inside-out patches in a reversible manner whereas anti-TRPC7 had no effect. Ab, mean
data showing the effect of antibodies raised against all TRPC proteins on SOC activity in coronary artery. Note
that in the presence of their antigenic peptides (Ag) the inhibitory action of anti-TRPC1, -TRPC5 and -TRPC6 were
blocked. Ba and b, anti-TRPC1 and -TRPC5 antibodies inhibited SOCs in mesenteric artery whereas anti-TRPC6 and
-TRPC7 had no effect. Ca and b, anti-TRPC1, -TRPC5 and -TRPC7 antibodies inhibited SOCs in portal vein whereas
anti-TRPC6 had no effect. Note anti-TRPC3 and -TRPC4 antibodies had no effect in any preparation (Ab, Bb and
Cb).
vein is different from the SOCs in these arteries. In these
experiments SOCs were initially evoked by CPA in the
cell-attached mode and then patches were excised into
the inside-out configuration where channel activity was
maintained without any appreciable rundown for up to
30 min in control conditions. Anti-TRPC antibodies raised
against different intracellular epitopes for each TRPC
subtype were then bath applied to the cytosolic surface
of the patch to measure directly the effect of antibodies on
single channel activity.
Figure 4A–C shows that SOC activity in coronary
and mesenteric arteries and portal vein was markedly
inhibited by over 80% using anti-TRPC1 and anti-TRPC5
antibodies. However there was differential sensitivity to
anti-TRPC6 and anti-TRPC7 antibodies. Anti- TRPC6
antibody inhibited SOC activity in coronary artery
(Fig. 4Aa and b) but not in mesenteric artery or portal
vein (Fig. 4B and C). In addition anti-TRPC7 antibody
markedly decreased SOC activity in portal vein (Fig. 4Ca
and b) but had no effect in coronary or mesenteric arteries
(Fig. 4A and B). The inhibitory actions of all anti-TRPC
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antibodies were completely blocked by preincubation with
their respective antigenic peptides (Fig. 4Ab, Bb and Cb)
and anti-TRPC3 and -TRPC4 antibodies had no effect on
SOC activity in myocytes from any blood vessel.
These data indicate that SOCs in coronary and
mesenteric arteries and portal vein have different
sensitivities to anti-TRPC antibodies, which further
demonstrates that SOCs in these vascular preparations
have different properties and may also suggest that these
SOC isoforms are composed of different TRPC subunits.
Coimmunoprecipitation of TRPC subunits from
coronary and mesenteric arteries and portal vein
vascular smooth muscle
Previous studies utilizing coimmunoprecipitation
techniques have demonstrated that TRPC channels can
combine to form heterotetrameric channel structures
(Goel et al. 2002; Hofmann et al. 2002; Strubing
et al. 2003). We therefore used this technique to see if
TRPC proteins identified from the functional effects of
anti-TRPC antibodies on channel activity shown above
Figure 5. Coimmunoprecipitation of TRPC channel proteins in coronary and mesenteric arteries and
portal vein
A, total tissue lysates from coronary artery were immunoprecipitated and then Western blotted (WB) using the
corresponding anti-TRPC antibodies. Note RT (rat testes) relates to positive control WB using anti-TRPC1 giving
bands of 90 kDa. Bands of 90 kDa were observed when Western blots were carried out with an anti-TRPC1
antibody in samples immunoprecipitated with TRPC1 and TRPC5 but not TRPC1 and antigenic peptide (Ag, Aa)
showing TRPC1 and TRPC5 protein can associate together. Western blots conducted using an anti-TRPC5 antibody
detected a band of 100 kDa when immunoprecipitation was carried out using anti-TRPC5 or anti-TRPC6 antibodies
demonstrating TRPC5 and TRPC6 protein can also associate in coronary artery. In mesenteric artery TRPC1 and
TRPC5 proteins are shown to coimmunoprecipitate with each other (Ba and b) whereas TRPC5 and TRPC6 protein
do not (Bc and d). In portal vein TRPC1 and TRPC5 and TRPC5 and TRPC7 were shown to associate with each
other (Ca–c).
could associate with one another in native coronary and
mesenteric arteries and portal vein.
Figure 5Aa shows that tissue lysates from coronary
artery immunoprecipitated with either anti-TRPC1 or
anti-TRPC5 antibodies and then blotted with a different
anti-TRPC1 antibody exhibited similar protein bands of
90 kDa. TRPC1-mediated 90 kDa bands were present in
positive control blots using rat testes (RT) cell lysates
and were absent in negative control experiments when
the anti-TRPC1 antibody was preincubated with its anti-
genic peptide (Fig. 5Aa). Furthermore Fig. 5Ab shows that
in blots from coronary artery and rat brain (RB) tissue
using anti-TRPC5, antibodies produced bands of 100 kDa
following immunoprecipitation with either an alternative
anti-TRPC5 antibody, or an anti-TRPC6 antibody. These
experiments provide evidence that association between
TRPC1 and TRPC5 and between TRPC5 and TRPC6
proteins can occur in coronary artery.
Figure 5B and C illustrates similar experiments using
lysates from mesenteric artery and portal vein and shows
that associations between TRPC1 and TRPC5 proteins can
also occur in both these vascular tissues. However Fig. 5Bc
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and d shows that in mesenteric artery there is no resolvable
combination of TRPC5 and TRPC6 or TRPC5 and TRPC7
proteins whereas Fig. 5Cb and c shows that in portal vein
associations between TRPC5 and TRPC7 proteins do occur
but combinations between TRPC5 and TRPC6 proteins do
not.
These data provide evidence that association between
TRPC1 and TRPC5 proteins occurs in coronary and
mesenteric arteries and portal vein whereas association
between TRPC5 and TRPC6 proteins only occurs in
coronary artery and association between TRPC5 and
TRPC7 proteins only occurs in portal vein. Interestingly
these results correspond exactly to the differential
sensitivities of single SOC currents to anti-TRPC anti-
bodies in these preparations (see above), which further
indicates that SOC isoforms described in the present work
may be produced by different compositions of TRPC
proteins.
Effect of flufenamic acid on SOCs in coronary
and mesenteric arteries and portal vein
To further investigate the diverse properties of SOCs
in these vascular preparations we studied the effects of
flufenamic acid (FFA) on channel activity induced by
PDBu in outside-out patches. In expression systems FFA
has been shown to increase TRPC6 and inhibit the activity
of all other TRPC channels (Inoue et al. 2001).
Figure 6A and D shows that the mean NPo of PDBu-
evoked SOC activity in coronary artery was significantly
increased by about twofold from a control value of
0.09 ± 0.04 to 0.18 ± 0.07 in the presence of 100 μm FFA
Figure 6. Differential effects of FFA on
SOCs in outside-out patches from coronary
and mesenteric arteries and portal vein
A, PDBu-evoked SOCs at −80 mV were
significantly enhanced in a reversible manner by
FFA (100 μM) in coronary artery. B and C, FFA
decreased PDBu-induced SOC activity in
mesenteric artery and portal vein. D, mean data
of the effect of FFA on SOC activity in three
vascular preparations (n = 5 of each).
(n = 5, P < 0.05). In contrast Fig. 6B, C and D illustrates
that FFA significantly reduced PDBu-evoked SOCs in
mesenteric artery and portal vein by 92 ± 10% (n = 4,
P < 0.05) and 91 ± 9% (n = 5, P < 0.05), respectively.
These data demonstrate pharmacological differences
between the SOCs in coronary and mesenteric arteries and
portal vein and also support the idea that TRPC6 proteins
contribute to the molecular structure of SOCs in coronary
artery but not in mesenteric artery or portal vein.
Discussion
In the present work we have investigated the physiological
properties of native SOCs in myocytes from different
blood vessels and the major finding is that SOCs in
coronary and mesenteric arteries have markedly different
properties. These characteristics are summarized in Table 1
and indicate the existence of various SOC isoforms, which
may be explained by diverse structures involving TRPC
subunits.
Biophysical properties of SOCs in coronary
and mesenteric arteries
Comparison of whole-cell currents demonstrated that
CPA evoked a conductance with a linear I–V relationship
in coronary artery whereas a pronounced outwardly
rectifying curve was observed in mesenteric artery
(Table 1). The clear difference in the rectifying properties
and reversal potential values of the whole-cell currents
suggested that the CPA-induced conductance was not
identical in the two preparations. A notable feature was
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that in the physiological range of membrane potentials
(−50 to −60 mV) the CPA-evoked inward current was
approximately sixfold greater in coronary compared to
mesenteric artery. In the latter preparation the rectifying
properties of the conductance permitted little inward
current at physiological membrane potentials.
Single channel recording also illustrated different
properties of the unitary conductance in coronary and
mesenteric arteries. The single channel conductance was
significantly larger in coronary compared to mesenteric
artery in 1.5 mm [Ca2+]o (Table 1) and this difference was
even more marked in 0 mm [Ca2+]o in which the unitary
conductance was about 2.7 pS and 7.5 pS, respectively, in
coronary and mesenteric arteries (Table 1). It appears that
extracellular Ca2+ ions have a blocking effect on the SOC
in mesenteric artery but not in coronary artery myocytes.
However these differences in single channel properties
strongly indicate a difference in the structure of the SOCs
in coronary and mesenteric artery myocytes.
The NPo value in coronary artery was threefold greater
than in mesenteric artery myocytes. There were the same
number of channels per patch in the two preparations
and therefore there appears to be a greater probability of
channel opening in coronary artery myocytes. The larger
unitary conductance coupled with increased probability
of SOC opening is likely to contribute to the larger inward
current observed in coronary compared to mesenteric
artery.
PKC-mediated activation of SOCs
Despite the differences in biophysical properties of SOCs
in coronary and mesenteric arteries there appeared to be
a common activation mechanism. Thus, PKC inhibitors
markedly reduced CPA- and BAPTA-AM-evoked channel
activity in coronary artery (present work) and in
mesenteric artery (Saleh et al. 2006). Also phorbol esters,
the DAG analogue OAG and a PKC catalytic subunit
potently stimulated SOC activity in both preparations.
These results implicate an important role for PKC in
activation of SOCs. However, an alternative pathway
involving calcium-influx factors, Ca2+-independent
phospholipase A2 and production of lysophospholipids
have been proposed to activate SOCs in other vascular
myocytes (Smani et al. 2004, 2007; Park et al. 2008). The
ability of PKC and lysophospholipids to activate these
channels may be related to multimodal gating of SOCs,
which has been recently reviewed (Albert et al. 2007).
Differential sensitivity of SOCs in coronary and
mesenteric arteries and portal vein to anti-TRPC
antibodies
There is much evidence that TRPC proteins form SOCs
in several cell types although little is known about the
role of TRPCs in mediating SOCs in vascular smooth
muscle (Large, 2002; Beech et al. 2004; Albert et al.
2007). We explored TRPC properties of native SOCs
in freshly dispersed myocytes by applying anti-TRPC
antibodies to the cytoplasmic surface of inside-out patches
in which SOCs had been stimulated. Using this approach
we have observed a high degree of selectivity with several
available anti-TRPC antibodies (Albert et al. 2006a; Saleh
et al. 2006; Peppiatt-Wildman et al. 2007). In the present
experiments we also investigated the sensitivity of a SOC
to anti-TRPC antibodies in rabbit portal vein myocytes
for comparison since we have previously characterized
the whole-cell and single channel properties of this
conductance (Albert & Large, 2002a,b; Liu et al. 2005a,b).
Anti-TRPC1 and anti-TRPC5 antibodies (two different
antibodies raised against different epitopes for each TRPC
subunit) were found to produce marked inhibition of SOC
activity in both arteries and portal vein (Table 1). This
is not a non-specific action of these antibodies against
non-selective cation channels since the same anti-TRPC1
and -TRPC5 antibodies have no effect against native
TRPC3 channels in rabbit ear artery, TRPC6 channels in
rabbit mesenteric artery or TRPC3/TRPC7 channels in
rabbit coronary artery myocytes (Albert et al. 2006a; Saleh
et al. 2006; Peppiatt-Wildman et al. 2007). A particularly
novel finding was that anti-TRPC6 antibody (two different
forms) reduced channel activity in coronary but not in
mesenteric artery or portal vein. In addition anti-TRPC7
antibody reduced channel activity in portal vein but
not in coronary or mesenteric arteries (Table 1). In all
cases inhibitory effects of antibodies were blocked by
preincubation with their respective antigenic peptides,
which were designed from predicted intracellular regions
of their respective TRPC channel proteins. Anti-TRPC3
and anti-TRPC4 antibodies had no effect on SOCs in any
preparation although the anti-TRPC3 antibody has been
shown to block the constitutively active ROC in ear artery
(Albert et al. 2006b) and ET-1-induced ROC in coronary
artery (Peppiatt-Wildman et al. 2007). These data showing
that the native SOCs display differential sensitivities to
anti-TRPC antibodies provide evidence that the three
preparations express SOCs which exhibit distinct TRPC
properties. It was clear in all three preparations that CPA
evoked only a single resolvable conductance in our single
channel recordings. Therefore although we are extremely
cautious about assigning precise molecular identification,
a simple explanation is that the SOC in each vascular
preparation is composed of different heterotetrameric
TRPC structures as detected by different antibodies.
Accordingly one interpretation of our data is that
SOCs contain TRPC1, TRPC5 and TRPC6 in coronary
artery, TRPC1 and TRPC5 in mesenteric artery and
TRPC1, TRPC5 and TRPC7 in portal vein and the
diverse compositions confer different properties on
the ion channels. Support for this was provided by
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coimmunoprecipitation experiments in which evidence
for association of TRPC1 and TRPC5 was found in all
three preparations but interactions between TRPC5 and
TRPC6 only occurred in coronary artery and TRPC5
and TRPC7 only associated in portal vein, even though
TRPC6 and TRPC7 proteins are highly expressed in
portal vein and coronary artery, respectively (Inoue et al.
2001; Peppiatt-Wildman et al. 2007). Interestingly the
conductance value of co-expressed TRPC1 and TRPC5
proteins (about 5 pS, Strubing et al. 2001) is similar to the
conductance values of SOCs in coronary and mesenteric
arteries and portal vein (between 2 and 3 pS), which
we show have TRPC1 and TRPC5 properties. Further
evidence for TRPC6 as a component of SOCs in coronary
artery was that FFA potentiated SOC activity in this
preparation but inhibited SOC activity in mesenteric
artery and portal vein. It has been shown that FFA
selectivity increases expressed TRPC6 activity but inhibits
all other TRPC channels in expression systems (Inoue et al.
2001). Also IP3 has been shown to potentiate expressed
TRPC7 channel activity but not TRPC6 (Estacion et al.
2004; Shi et al. 2004). IP3 potentiated SOC activity in portal
vein (Liu et al. 2005b), which was inhibited by anti-TRPC7
antibody, but not in coronary or mesenteric arteries where
SOC activity was unaffected by anti-TRPC7 antibodies.
Hence it seems that differences in important physiological
characteristics of SOCs in the three vascular preparations
can be explained by diverse TRPC composition of the
native channels.
The above data suggesting combinations of TRPC5
and TRPC6 and of TRPC5 and TRPC7 proteins are
involved in composing native SOCs are novel interactions
that go against the original principles of TRPC
heteromultimerization that suggested TRPC1, TRPC4 and
TRPC5 or TRPC3, TRPC6 and TRPC7 may associate
to form ion channels (Goel et al. 2002; Hofmann et al.
2002). However, more recently it has been proposed
that functioning cation channels may be composed of
subunits from both these groups (Strubing et al. 2003;
Liu et al. 2005; Poteser et al. 2006). However, for
more precise information on the molecular make-up
of these native SOCs, comparison of the proposed
heterotetrameric structures in expression systems with
native SOCs would be required. Molecular techniques
to elucidate the structure of these native TRPC channels
will be problematic since these experimental approaches
require cell culture during which vascular smooth muscle
cells undergo fundamental changes (e.g. see Owens, 1995
for review). Also recently it has been shown that there is
reorganization of intracellular Ca2+ stores during culture
of vascular myocytes (Ng et al. 2008), which is likely
to exacerbate difficulties in investigating store-operated
events. Moreover it has been demonstrated that TRPC
expression alters during cell culture of vascular myocytes
(Bergdahl et al. 2005), which would amplify the difficulties
of using siRNA approaches with heterotetrameric channel
structures. Recently it was shown that CPA-evoked
responses in wild-type and TRPC1−/– mice were similar,
indicating that TRPC1 is not an essential component of
SOCs in vascular smooth muscle (Dietrich et al. 2007).
However the present work indicates that not only TRPC1
but also TRPC5, as also suggested by Xu et al. (2006), and
TRPC6 and TRPC7 may be components of native SOCs.
Consequently in TRPC1−/– mice it is possible that these
other TRPC proteins can compensate for the loss of TRPC1
as was previously seen with TRPC6−/– mice (Dietrich et al.
2005).
Conclusion
It is concluded that there are several native SOC
isoforms in vascular smooth muscle and we provide
evidence that these differences may results from a diversity
of TRPC composition. It is increasingly evident that
vascular smooth muscle contains a complex array of
TRPC ion channels with different physiological properties.
For example, in rabbit coronary artery ET-1 activates
two distinct conductances, one with TRPC3 and TRPC7
properties (Peppiatt-Wildman et al. 2007) and the second
with TRPC1, TRPC5 and TRPC6 characteristics (present
work). However, the marked pharmacological differences
suggest that it might be possible to develop selective
inhibitors of these TRPC conductances to therapeutic
advantage.
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